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Abstract 
Polymers which can respond to externally applied stimuli have found much application in the 
biomedical field due to their (reversible) coil-globule transitions. Polymers displaying a lower 
critical solution temperature are the most commonly used, but for blood-borne (i.e. soluble) 
biomedical applications the application of heat is not always possible, nor practical. Here we 
report the design and synthesis of poly(oligoethylene glycol methacrylate)-based polymers 
whose cloud points are easily varied by alkaline phosphatase-mediated dephosphorylation. 
By fine-tuning the density of phosphate groups on the backbone, it was possible to induce an 
isothermal transition: A change in solubility triggered by removal of a small number of 
phosphate esters from the side chains activating the LCST-type response. As there was no 
temperature change involved, this serves as a model of a cell-instructed polymer response. 
Finally, it was found that both polymers were non cytotoxic against MCF-7 cells (at 1 
mg.mL-1), which confirms promise for biomedical applications.  
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Introduction 
Responsive polymers provide a valuable tool in drug delivery with common stimuli including 
pH, light, and electric fields.1-3 Thermoresponsive polymers are by far the most common with 
those displaying a lower critical solution temperature (LCST), such as pNIPAM (poly(N-
isopropyl acrylamide)) being widely studied, along with poly(oligoethylene glycol 
methacrylates),4, 5 poly(dimethylamino ethyl methacrylate)6, 7 or poly(vinyl alcohol) 
copolymers.8 However, for them to be applied biomedically a temperature response is not 
always desirable or even possible, meaning the incorporation of alternative responsive 
components is essential.9  Enzymes are a particularly attractive stimulus where specific 
responses are desired given their highly specialised nature and unique localisation to certain 
tissues or even cells. For example, azoreductase is produced by the microbial flora present in 
the colon;10 pepsin is present at high levels in the stomach11 and a variety of digestive 
enzymes exist throughout the gastrointestinal tract.12 They can also provide valuable 
biomarkers with a range of stress and disease states characterised by imbalances in enzyme 
expression and activity.13 For instance, hepsin is a protease overexpressed in the early stages 
of prostate cancer,14 cathepsins are released at inflammatory sites15 and widely used as a 
release mechanism in polymer-drug conjugates and matrix metalloproteinases have been 
linked to vascular disease and tumour growth.16, 17 The use of enzymes to trigger a specific 
response and hence manipulate the structures and pharmacokinetics of polymer-based 
materials has received increasing attention.18-20 Rao and Khan prepared polymeric micelles 
containing an azoreductase-susceptible azobenzene linkage at the copolymer junction of an 
amphiphilic diblock copolymer. Treatment of the aqueous-assembled micelle with this 
enzyme, in the presence of the coenzyme NADPH, cleaved the junction and disrupted the 
micellar assembly.21 A similar approach has been employed by Harnoy et al. who used 
penicillin G amidase to disrupt phenyl acetamide-containing micelles.22 Thayumanavan and 
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co-workers have prepared dendrimer-based amphiphilic nanocontainers containing ester units 
which are cleaved to release encapsulated guests in the presence of porcine liver esterase.23 
Fuchs et al. have prepared nanoparticles from polystyrene-peptide-polystyrene triblock 
copolymers with the peptide susceptible to different enzymes depending on its sequence: 
Trypsin or hepsin could be used depending on whether a Gly-Phe-Phe or Arg-Gln-Leu-Arg-
Val-Val-Gly-Gly sequence was present respectively.24 Enzymes have also been shown to 
promote material assembly. For example, Hu and Messersmith have used transglutaminase as 
a gelation agent in the assembly of hydrogels25 whilst peroxidases26 and tyrosinases27 have 
also been used.  
A particularly interesting class of enzymes are the phosphatases which catalyse the hydrolysis 
of phosphate monoesters.28 Within this family, alkaline phosphatase (ALP) is found in the 
liver and bone, as well as in the intestinal lining, placenta and the kidney, playing an 
important role in mineralisation and osteogenesis.29, 30 Elevated levels of the enzyme can 
therefore be implicated in Paget’s bone disease,31 whilst depleted levels have been linked 
with Wilson’s disease32 and in a range of cancer types.33 Xu and co-workers used ALP to 
trigger hydrogelation by neutralising an ionic group on an amino acid derivative, rendering it 
a small-molecular hydrogelator.34 Wang et al. have prepared a phosphatase-responsive 
system using electrostatic interactions between a double hydrophilic block copolymer 
comprising poly(ethylene glycol), poly(L-lysine hydrochloride) and adenosine 5’-
triphosphate (ATP) to form a superamphiphile in aqueous solution. Addition of ALP 
hydrolyses ATP to single phosphates and a neutral adenine group prompting aggregate 
disassembly.35 Zelzer and co-workers have prepared a peptide-based surface whose chemical 
properties change upon the catalytic action of ALP.36 
The ability to combine the specificity of an enzymatic action with other complex responses 
holds great promise to develop multi-responsive systems.37 For example, thermally-
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responsive systems typically undergo an abrupt solubility change with an aqueous polymer 
solution either phase separating (LCST), or a phase-separated mixture re-solubilising (UCST, 
upper critical solution temperature) upon heating. To fine-tune the LCST, the introduction of 
hydrophobicity/philicity to the system decreases/increases the transition temperature 
respectively.38, 39 It is therefore reasonable to assume that the phosphatase-driven 
dephosphorylation of a phosphate to hydroxyl functional group will decrease the 
hydrophilicity of the system and hence affect the LCST, allowing an isothermal9 change in 
polymer solubility without the need for a change in temperature. Gibson and co-workers have 
demonstrated glutathione40, 41 and Fe3+ isothermal responses42 and there are othrt examples of 
ion43 and even bacteria- responsive polymers.44  
It has been observed that upon passing through the LCST, polymers can gain entrance to cells 
due their increased lipophilicity and membrane permeability.45, 46 For example, Alexander 
and co-workers have prepared chemo-therapy loaded nanoparticles which display enhanced 
uptake and cytotoxicity upon heating above the particle thermal transition temperature.47 In 
addition to polymer nanoparticles,45 other structures which have employed this property to 
enhance cell uptake include liposomes,48 hydrogel submicron particles49  and elastin-like 
polypeptides.50, 51 An attractive extension of this concept would be to trigger cell uptake using 
localised biochemical gradients (such as local enzyme concentration) to enable cell uptake 
guided by the cellular physiology rather than external heating, and provide an alternative 
approach to the more traditional, receptor-mediated uptake pathways.52-56  
Considering the potential for using an LCST-type transition to drive cellular uptake,45, 47, 49 
this manuscript describes the synthesis and evaluation of phosphate-containing polymers and 
their elaboration into isothermally responsive polymers, capable of undergoing their coil-
globule transition at constant temperature. Preliminary cytotoxicity evaluation is also 
presented.  
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Materials and Methods 
Phosphorus (V) oxychloride (≥ 99.0 %), 2-hydroxyethyl methacrylate (97.0 %), triethylamine 
(≥ 99.0 %), 4-cyano-4-(phenylcarbonothioylthio) pentanoic acid (> 97.0 %), 4,4’-azobis(4-
cyanovaleric acid) (≥ 98.0 %), mesitylene (analytical standard), 2-mercaptoethanol (≥ 99.0 
%), tribasic potassium phosphate (reagent grade, ≥ 98.0 %), carbon disulfide (≥ 99.0 %) and 
benzyl bromide (98.0 %) were purchased from Sigma-Aldrich. Oligo(ethylene glycol, 
average Mn = 300 g.mol-1), methyl ether methacrylate and di(ethylene glycol) methyl ether 
methacrylate (95.0 %) were also purchased from Sigma-Aldrich and inhibitors removed by 
passing through a column of basic alumina prior to polymerisation. Hostasol methacrylate 
was kindly donated by the Haddleton group at the University of Warwick. 2-
(dodecylthiocarbonothioylthio)-2-methylpropanoic acid was synthesised as previously 
described.41 Calf Intestinal Alkaline Phosphatase (10,000 U/mL) was purchased from New 
England Biolabs Inc. The enzyme was packaged with a 10x NEBuffer 3. This was diluted 10-
fold prior to use with the resulting 1x NEBuffer 3 containing 100 mM NaCl, 50 mM Tris-
HCl, 10 mM MgCl2, 1 mM dithiothreitol, pH 7.9 at 25 °C. The phosphate colorimetric assay 
kit was purchased from BioVision. A standard curve was prepared by diluting 10 µL of the 
supplied 10 mM Phosphate Standard to 990 µL dH2O to give a 100 µM working standard. 
Desired standard concentrations were prepared by mixing the 10 mM standard with deionised 
water to give a total volume of 200 µL. The colorimetric phosphate reagent was used as 
received. 
MCF-7 (ER + ve breast cancer cell line, wild type) was donated by Tenovus centre for 
Cancer research (Cardiff, UK). Tissue culture media and reagents were from Lonza, UK. 
Reagents for phosphate buffered saline (PBS) for cell culture were purchased from Sigma 
Aldrich, UK and PBS (pH 7.4) was prepared in house using UHQ water. 3-(4,5-Dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT, powder) and Dimethyl sulfoxide 
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solution (DMSO) were purchased from Sigma Aldrich, UK. MTT solution (5 mg.mL-1) was 
prepared in PBS (pH 7.4). 
Physical and Analytical Methods 
SEC analysis was performed on one of two systems:  
(i) Dimethylformamide: Varian 390-LC MDS system equipped with a  PL-AS RT/MT 
autosampler, a PL-gel 3 µm (50 x 7.5 mm) guard column, two PL-gel 5 µm (300 x 7.5 mm) 
mixed-D columns using DMF with 5 mM NH4BF4 at 50 °C as eluent at a flow rate of 1.0 
mL.min-1. The SEC system was equipped with ultraviolet (UV)/visible (set at 280 and 461 
nm) and differential refractive index (DRI) detectors. Narrow molecular weight PMMA 
standard (200 - 1.0 x 106 g.mol-1) were used for calibration using a second order polynomial 
fit. 
(ii) Aqueous: Varian 390-LC MDS system equipped with a PL-AS RT/MT autosampler, an 
aquagel-OH  (50 x 7.5 mm) guard column, one PL-aquagel-OH 40 8 µm (300 x 7.5 mm) and 
one PL-aquagel-OH 30 8 µm (300 x 7.5 mm) column using a buffer comprising 0.2 M 
NaNO3 and 0.01 M NaH2PO4.2H2O adjusted to pH 8.2 with 1 M NaOH at 30 °C as eluent at 
a flow rate of 1.0 mL.min-1). The SEC system was equipped with a differential refractive 
index (DRO) detector. Narrow molecular weight PEO standards (100 – 1.0 x 105 g.mol-1) 
were used for calibration using a second order polynomial fit. 
NMR spectroscopy (1H, 13C, 31P) was conducted on a Bruker DPX-300, Bruker DRX-500 or 
Bruker AV III 600 spectrometer using deuterated chloroform or deuterated methanol as 
solvent. All chemical shifts are reported in ppm (δ) relative to the solvent used. FTIR spectra 
were acquired using a Bruker Vector 22 FTIR spectrometer with a Golden Gate diamond 
attenuated total reflection cell. A total of 64 scans were collected on samples in their native 
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state. High resolution mass spectra were recorded on a Bruker Electrospray Ultra-High 
Resolution tandem TOF mass spectrometer using electrospray ionisation (ESI) in either 
positive or negative mode on samples prepared in methanol.  Cloud points were determined 
by turbidimetric analysis using either an Optimelt MPA100 system (Stanford Research 
Systems) or an Agilent Cary 60 UV/visible spectrophotometer with the absorbance monitored 
at 650 nm. A heating rate of 1 °C.min-1 was used in both cases and the recorded turbidimetry 
curve was normalised between values of 0 and 1. The cloud point was defined as the 
temperature corresponding to a normalised absorbance of 0.5. 
 
Methods 
Cell viability (MTT-Assay). MCF-7 cells were cultured in RPMI 1640 growth medium 
supplemented with 5% fetal bovine serum under standard tissue culture conditions (37 °C, 
humidified 5% CO2 atmosphere). Stock solutions of the polymer (4 mg.mL-1) were prepared 
in complete growth medium, sterile filtered (0.2 µm) and then further diluted with complete 
growth medium. MCF-7 cells were seeded (4 × 104 cells per mL) in a 96-well plate and 
incubated for 24 h to allow attachment. Then, fresh complete growth medium containing the 
polymers was added (concentrations 0 – 1 mg.mL-1. After treatment, cytotoxicity was 
assessed by MTT assay as previously reported.57 Briefly, MCF-7 cells were incubated with 
the polymer solutions. After 67 h, MTT solution (20 µL) was added to each well and the cells 
were incubated for further 5 h after which 100 µL of DMSO was added to dissolve the purple 
crystals formed. The plates were read at 570 nm using a SPECTRA max UV spectrometer 
(Bio-Rad). Data represent the mean of at least three independent experiments and cell 
viability is expressed as % of control (complete growth medium without polymers).  
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Example polymerisation of 2-(methacryloyloxy)ethyl phosphate using 4-cyano-4-
(phenylcarbonothioylthio) pentanoic acid  
2-(methacryloyloxy)ethyl phosphate (1.00 g, 4.76 mmol), 4-cyano-4-
(phenylcarbonothioylthio) pentanoic acid (13.30 mg, 47.61 µmol, 0.01 equiv) and 4,4’-
azobis(4-cyanovaleric acid) (2.70 mg, 9.63 µmol (0.002 equiv) were added to a vial fitted 
with stir bar and rubber septum and dissolved in methanol (4 mL). Mesitylene (200 µL) was 
added as internal reference and the mixture stirred (5 mins). An aliquot of this starting 
mixture was removed for 1H NMR spectroscopic analysis. The mixture was degassed by 
bubbling through nitrogen gas for 30 mins and placed in an oil bath thermostated at 65 °C for 
7 hrs. The reaction was quenched in liquid nitrogen, an aliquot removed and conversion 
determined by 1H NMR spectroscopy. The product was purified three times by precipitation 
from methanol into cold diethyl ether, the solid isolated by centrifugation and dried to yield a 
pale pink solid. Conversion (NMR): 54.7 % Mn (theoretical): 11500 g.mol-1; Mn (SEC): 
38000 g.mol-1; Mw/Mn (SEC): 2.20. 
Example polymerisation of 2-(methacryloyloxy)ethyl phosphate using 2-
(dodecylthiocarbonothioylthio)-2-methylpropanoic 
2-(methacryloyloxy)ethyl phosphate (1.00 g, 4.76 mmol), 2-(dodecylthiocarbonothioylthio)-
2-methylpropanoic acid (17.35 mg, 47.58 µmol, 0.01 equiv) and 4,4’-azobis(4-cyanovaleric 
acid) (2.70 mg, 9.63 µmol, 0.005 equiv) were added to a vial fitted with stir bar and rubber 
septum and dissolved in methanol (4 mL). Mesitylene (200 µL) was added as internal 
reference and the mixture stirred (5 mins). An aliquot of this starting mixture was removed 
for 1H NMR spectroscopic analysis. The mixture was degassed by bubbling through nitrogen 
gas for 30 mins and placed in an oil bath thermostated at 65 °C for 10 hrs. The reaction was 
quenched in liquid nitrogen, an aliquot removed and conversion determined by 1H NMR 
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spectroscopy. The product was purified three times by precipitation from methanol into cold 
diethyl ether, the solid isolated by centrifugation and dried to yield a pale yellow solid. 
Conversion (NMR): 67.0 % Mn (theoretical): 14100 g.mol-1; Mn (SEC): 27700 g.mol-1; 
Mw/Mn (SEC): 2.17. 
Polymerisation of oligo(ethylene glycol) methyl ether methacrylate using 4-cyano-4-
(phenylcarbonothioylthio) pentanoic acid 
Oligo(ethylene glycol) methyl ether methacrylate (average Mn = 300 g.mol-1) (1.00 g, 2.5 
mmol), 4-cyano-4-(phenylcarbonothioylthio) pentanoic acid (13.97 mg, 50.00 µmol, 0.02 
equiv) and 4,4’-azobis(4-cyanovaleric acid) (2.80 mg, 10.00 µmol, 0.004 equiv) were added 
to a vial fitted with stir bar and rubber septum and dissolved in dioxane (3 mL). Mesitylene 
(100 µL) was added as internal reference and the mixture stirred (5 mins). An aliquot of this 
starting mixture was removed for 1H NMR spectroscopic analysis. The mixture was degassed 
by bubbling through nitrogen gas for 30 mins and placed in an oil bath thermostated at 70 °C 
for 4 hrs. The reaction was quenched in liquid nitrogen, an aliquot removed and conversion 
determined by 1H NMR spectroscopy. The product was purified three times by precipitation 
from dioxane into cold diethyl ether, the solid isolated by centrifugation and dried to yield a 
waxy pink solid. Conversion (NMR): 44.2 %; Mn (theoretical): 8800 g.mol-1; Mn (SEC): 
11300 g.mol-1; Mw/Mn (SEC): 1.18. 
 
Example co-polymerisation of 2-(methacryloyloxy)ethyl phosphate and diethylene 
glycol methyl ether methacrylate using 4-cyano-4-(phenylcarbonothioylthio) pentanoic 
acid 
12 
Diethylene glycol methyl ether methacrylate (1.03 g, 5.47 mmol), 2-(methacryloyloxy)ethyl 
phosphate (0.13 g, 607.92 µmol), 4-cyano-4-(phenylcarbonothioylthio) pentanoic acid (17.00 
mg, 60.79 µmol, 0.01 equiv) and 4,4’-azobis(4-cyanovaleric acid) (3.41 mg, 12.16 µmol, 
0.002 equiv) were added to a vial fitted with stir bar and rubber septum and dissolved in 
methanol (4 mL). Mesitylene (200 µL) was added as internal reference and the mixture 
stirred (5 mins). An aliquot of this starting mixture was removed for 1H NMR spectroscopic 
analysis. The mixture was degassed by bubbling through nitrogen gas for 30 mins and placed 
in an oil bath thermostated at 65 °C for 6.5 hrs. The reaction was quenched in liquid nitrogen, 
an aliquot removed and conversion determined by 1H NMR spectroscopy. The product was 
purified three times by precipitation from methanol into cold diethyl ether, the solid isolated 
by centrifugation and dried to yield a waxy pink solid. Conversion (NMR): 23.3 %; Mn 
(theoretical): 4400 g.mol-1; Mn (SEC): 6200 g.mol-1; Mw/Mn (SEC): 1.30. 
Phosphatase Assays 
General assay conditions for colorimetric determination of phosphate release 
A 105 µg.mL-1 stock solution of polymer in water was prepared. In a 96-well plate, in 
triplicate was added 188 µL of 1x NEBuffer 3 solution (diluted from the 10x concentrated 
solution provided by supplier), 10 µL of polymer solution and 2 µL calf intestinal alkaline 
phosphatase (10,000 U/mL from supplier = 20 U. U = ‘1 unit of activity as specified by the 
supplier. 1 unit should hydrolyse 1 µmol in 1 mL in 1 minute. In this assay 20 Units were 
added to 0.1 µmol phosphate groups and therefore was in excess). The plate was then covered 
and incubated at 37 °C. At a given time-point, 30 µL of the phosphate reagent was mixed into 
each well, incubated at 37 °C for 90 mins and the absorbance at 650 nm measured. The molar 
concentration and hence percentage of phosphate released was determined by comparing to a 
known calibration curve. 
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Assay determining the effect of phosphatase on polymer cloud point 
Polymer was dissolved in 1x NE Buffer 3 and calf intestinal alkaline phosphatase added to 
give a final polymer concentration of 5 mg.mL-1. This mixture was stirred at 37 °C for 24 hrs. 
After this time, an aliquot of the mixture was transferred to a melting point tube and the cloud 
point determined at a heating rate of 1 °C.min-1. 
Turbidimetric assay for phosphatase-mediated isothermal polymer response 
A 5.56 mg.mL-1 solution of polymer in 1x NEBuffer 3 was prepared. 2 x 90 µL aliquots of 
this stock were transferred into individual wells of a 96-well plate. The plate was left to 
incubate at 34 °C in the plate reader for 35 mins. The plate was then removed and the well 
volume made to 100 µL with distilled water or calf intestinal alkaline phosphatase. The plate 
was re-incubated at 34 °C and the absorbance at 650 nm was recorded for an additional 25 
mins. 
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Results and Discussion 
To access a polymer which would undergo a switch in its cloud point (LCST) upon loss of a 
phosphate group, triggered by (the enzyme) alkaline phosphatase, the monomer ethylene 
glycol methacrylate phosphate (Phos-HEMA) was synthesised by reaction of phosphorus 
oxychloride with hydroxyethyl methacrylate, Scheme 1. This reaction produced the desired 
monomer in good yield, with negligible traces of the undesired diene impurity. 1H NMR 
spectroscopic analysis revealed vinyl proton peaks at 6.17 and 5.67 ppm, together with two 
CH2 groups and one CH3 group at 4.37, 4.21 and 1.97 ppm respectively (Figure 6.3A). 
Doublets at 64.1 and 63.5 ppm observed in the 13C NMR spectrum on account of coupling 
with the phosphorus atom and the single peak observed by 31P NMR spectroscopic analysis 
further confirmed monomer structure and purity (see ESI). 
 
Scheme 1 Synthetic scheme for the preparation of Phos-HEMA. 
With phosphorylated monomer to hand, phosphate-functional polymers were prepared by the 
RAFT process. Given the few reports on this, preliminary experiments were performed to 
better understand the polymerisation rate, and to confirm the controlled nature. Two chain 
transfer agents, 4-cyano-4-(phenylcarbonothioylthio) pentanoic acid (CPADB) and 2-
(dodecylthiocarbonothioylthio)-2-methylpropanoic acid (DDMAT) were employed in a 
reaction mixture comprising [M]:[CTA]:[Initiator] = 100:1:0.2, and an initial monomer 
concentration of 1.19 M. Mesitylene was used as an internal standard and conversion was 
monitored by 1H NMR spectroscopy, following the change in integral of vinyl proton peak 
relative to this standard. Polymerisation was observed to be faster using the trithiocarbonate 
compared to the dithiobenzoate, with approximately 85 % conversion reached after 10 and 24 
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hours respectively (Figure 1). First order kinetics were observed with both RAFT agents 
indicating a constant number of propagating chain ends; a key characteristic of controlled 
radical processes.58 This indicated that both RAFT agents were suitable. 
 
Figure 1 Kinetic analysis of the RAFT polymerisation of Phos-HEMA: (A) RAFT agents 
used; (B) pseudo first order kinetic plot. 
A library of poly(Phos-HEMAs) were prepared using the dithiobenzoate RAFT agent and the 
results of this summarised in Table 1. At higher molecular weights, the dispersity becomes 
broader than typically desired for controlled radical methodologies, with a high molecular 
weight shoulder beginning to develop. This may be an artefact of the SEC system used – for 
instance, partial deprotonation of the phosphate functionality may influence the 
hydrodynamic volume of some polymer chains or promoting interaction with the column 
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materials. For our purpose however, RAFT was simply used as a facile route towards the 
preparation of phosphate-functional polymers. To confirm the presence of this functional 
group, 31P NMR analysis of the purified material was performed and revealed a single 
phosphorus peak, confirming the presence of a phosphate group and hence the suitable 
application of the RAFT technique. Moreover, the use of a diene-free monomer ensured the 
poly(diester) impurities observed in previous reports59 was not seen in our case.  
Table 1 Characterisation of pPhos-HEMA samples prepared using 4-cyano-4-
(phenylcarbonothioylthio) pentanoic acid in this study. 
Polymer [M]:[CTA] 
Conversion 
(%)a 
Mn(th) 
(g.mol-1)a 
Mn(SEC) 
(g.mol-1)b 
Mw/Mnb 
pPhos-HEMA-1 10 41.2 870 9400 1.24 
pPhos-HEMA-2 75 50.8 8000 30900 2.00 
pPhos-HEMA-3 100 54.7 11500 38000 2.20 
aDetermined by 1H NMR spectroscopy relative to an internal standard (mesitylene). 
Theoretical molecular weight is determined by the feed ratio, and conversion, assuming a 
linear increase in molecular weight with conversion; bDetermined by SEC (aqueous) relative 
to PEO standards. 
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Figure 2 Characterisation of pPhos-HEMA. (A) Aqueous SEC of pPhos-HEMA-1/2/3; (B) 
31P NMR spectrum of pPhos-HEMA-1 in MeOD. 
With the panel of polymers to hand, the ability of calf intestinal alkaline phosphatase 
(CIALP) to cleave phosphate groups from the chain was investigated. A colorimetric assay 
was employed to monitor this reaction; briefly this assay uses malachite green and 
ammonium molybdate which, in the presence of a phosphate ion, forms a chromogenic 
complex with an intense absorption band around 650 nm, which can be calibrated against 
known phosphate solutions. To ensure biological relevance, all experiments were performed 
at 37 °C. pPhos-HEMA-3 was added to buffer followed by the enzyme and the absorbance 
at 650 nm measured after a 90 minute incubation time (Figure 3). Phosphate release was 
observed to be rapid with 38 % released after 30 min before plateauing at approximately 60 
% after 8 hours, either due to unwanted polymer interactions or due to the protein losing 
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catalytic activity. The produced poly(hydroxyethyl methacrylate), pHEMA is known to be 
water swellable, rather than water-soluble at chain lengths beyond approximately 20 repeat 
units and therefore will be less soluble.60, 61 Whilst no polymer precipitation was observed 
during the assay, the increasing hydrophobic character obtained upon dephosphorylation may 
result in the formation of globule-type micro-domains which could limit enzyme access to the 
remaining phosphate functional groups. A similar observation has been made by Amir et al. 
who used acid phosphate to dephosphorylate a diblock copolymer containing PEG-derived 
and phosphorylated styrene blocks. Incomplete dephosphorylation was observed which was 
attributed to the beginnings of a self-assembly process which shielded some phosphate 
groups from being accessed by the enzyme.62 
 
 
Figure 3 Percentage phosphate release from pPhos-HEMA-3 upon incubation with CIALP. 
 
To investigate whether the polymer chain length could influence the degree of phosphate 
release, the same assay was performed on polymers pPhos-HEMA-1 (Mn(theo) = 870 g.mol-1) 
and pPhos-HEMA-2 (Mn(theo) = 11500 g.mol-1). In each case, the mass of polymer used was 
fixed meaning despite the difference in chain length the number of phosphate groups in each 
sample is identical. All samples were incubated for 24 hours after which phosphate release 
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was measured, with all polymers exhibiting similar release profiles between 55 and 60 % 
(Figure 4). This observation suggests enzyme activity or access to dephosphorylation is 
independent of molecular weight (in the limited range tested), which makes the design of 
isothermally responsive polymers simpler using this motif (vide infra). Several controls were 
also performed to confirm the validity of the assay. Firstly, the absorbance of the kit in buffer 
was shown to be minimal confirming no interaction between the chromogenic complex and 
the solution salts. Polymer pPhos-HEMA-3 was also tested in the absence of enzyme 
(pPhos-HEMA-3 – CIP in Figure 4). Less than 10 % release (due to hydrolysis) was observed 
indicating the measured absorbance was due to the dephosphorylation of phosphate groups by 
CIALP, rather than by other non-specific mechanisms such as aqueous phosphate hydrolysis 
(Figure 4). Finally, a non-phosphate containing, water-soluble polymer was also tested – 
poly[oligo(ethylene glycol)300 methyl ether methacrylate], pOEGMA300 (ESI for details). A 
small change in absorbance which equated to approximately 10 % phosphate release was also 
observed suggesting the polymer may interfere with the colorimetric assay in some way 
though this was still significantly less than that observed for pPhos-HEMA-1/2/3 in the 
presence of the enzyme (Figure 4).  
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Figure 4 Phosphate release as a function of polymer structure. A) Phosphate release in 
presence of CIALP. Error bars represent standard deviation from minimum of 3 repeats; (B) 
Chemical structures of polymers employed. 
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The main aim of this study was to induce an isothermal switch based on a known thermo-
responsive polymer, triggered by CIALP. To achieve this, co-polymers of a known 
responsive polymer using poly(phosHEMA) as the enzymatic trigger were required. 
Diethylene glycol methyl ether methacrylate (DEGMA) was selected for this. It is known to 
have similar reactivity ratios to HEMA ensuring random co-polymers are obtained and it has 
a cloud point of around 26 °C in aqueous solution.63, 64 We therefore reasoned that addition of 
Phos-HEMA units would raise the cloud point, but upon enzymatic cleavage, reduce it, such 
that an isothermal transition at 37 °C could be obtained. To assess the effect of Phos-HEMA 
on the cloud point of the DEGMA-based co-polymers, a series of copolymers was prepared 
(Table 2). 
Table 2 Characterisation of poly(DEGMA-co-Phos-HEMA) samples prepared using 4-
cyano-4-(phenylcarbonothioylthio) pentanoic acid in this study. 
Polymer 
[DEGMA]:[phos-
HEMA]:[CTA] 
Conversion 
(%)a 
Mn(th) 
(g.mol-1)a 
Mn(SEC) 
(g.mol-1)b 
Mw/Mnb 
Pco1% 99:1:1 42.7 8000 7300 1.23 
Pco2.5% 97.5:2.5:1 45.9 8600 7200 1.21 
Pco5% 95:5:1 46.4 8800 6400 1.21 
Pco10% 90:10:1 23.3 4400 6200 1.30 
aDetermined by 1H NMR spectroscopy relative to an internal standard (mesitylene) assuming 
equal conversion of DEGMA and Phos-HEMA (Phos-HEMA vinyl proton peaks too poorly 
resolved for analysis); bDetermined by SEC (DMF inc. 5 mM NH4BF4) relative to PMMA 
standards. 
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SEC analysis indicated a controlled polymerisation, supporting our earlier (vide supra) 
arguments about column interactions of phosphate-rich polymers. The obtained molecular 
weights were in agreement with the monomer feed ratio for Pco1%, Pco2.5% and Pco5%, but 
Pco10% (most phosphate) gave lower conversion and hence lower molecular weight. Cloud 
point analysis of these polymers at 5 mg.mL-1 revealed an increase from 35 °C to 45 °C upon 
increasing the Phos-HEMA ratio from 1 % to 10 % (Figure 5), providing evidence of the 
successful incorporation of the monomer in the co-polymer structure. The very hydrophilic 
nature of Phos-HEMA means only small proportions are required to produce a cloud point 
with physiological relevance, which is desirable to ensure minimal enzymatic interaction are 
needed to induce the change. 
 
Figure 5 Characterisation of pDEGMA-co-Phos-HEMA: (A) Co-polymer chemical structure; 
(B) SEC characterisation; (C) Cloud point traces at a polymer concentration of 5 mg.mL-1 
(solid curves added to guide the eye only); (D) Cloud point as a function of co-polymer 
composition.  
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It was anticipated that the action of phosphatase on this polymer would trigger a decrease in 
cloud point by converting phosphate groups to less hydrophilic hydroxyl moieties (Figure 6). 
To test this hypothesis, a 5 mg.mL-1 solution of Pco5% was incubated with CIALP and the 
sample stirred at 37 °C for 24 hours. This polymer concentration was selected to ensure the 
change in turbidity (precipitation) observed upon passing through the cloud point would be 
sufficiently strong for detection by the instrument used (i.e. lower concentrations would 
respond, but not give such a large response). After this time, the sample was analysed by 
turbidimetry and a decrease in the cloud point by 4 °C and 8 °C was observed in the presence 
of 2 µL (2 units) and 10 µL (10 units) of enzyme respectively confirming the isothermal 
response (Figure 6B). 
 
Figure 6 Dephosphorylation of co-polymers by CIALP. (A) Change in chemical structure of 
poly(DEGMA-co-Phos-HEMA) upon incubation with CIALP; (B) Effect of CIALP on cloud 
point of Pco5% (solid curves are to guide the eye). 
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To confirm these observations were due to phosphate removal, two controls were performed. 
Firstly, the polymer was incubated without enzyme for a period of 24 hours and negligible 
change in cloud point was observed, confirming any shift is not due to direct hydrolysis of 
either the phosphate groups or the methacrylate backbone. Moreover, to verify the shift was 
not simply due to the additives present in the buffer used for analysis the non-phosphate-
containing pOEGMA300 was also analysed following 24 hour incubation with 10 µL CIALP 
(Figure 7). Minimal change was observed in this case with the cloud point actually increasing 
slightly, in contrast to the behaviour expected and observed if dephosphorylation was 
occurring (Figure 6B). In comparison to the assays performed on the homopolymers where a 
phosphate concentration of 25 µM was employed, the phosphate concentration in this test 
was nearly 50 x higher (~ 1.2 mM) and hence the effect of a larger enzyme volume is perhaps 
unsurprising.  
 
Figure 7 Effect of CIALP on POEGMAs. (A) Cloud point of Pco5% in 1x NEBuffer 3 after 
24 hours; (B) Cloud point of pOEGMA300 with and without 10 µL CIALP (solid curves are 
to guide the eye). 
 
The change in cloud point observed upon the addition of CIALP provided a window for an 
isothermal transition to be achieved and was tested using a turbidimetric assay (Figure 8). 
Pco5% was held at 34 °C, below its cloud point but above that observed in the presence of 10 
25 
µL CIALP. No increase in absorbance was observed until the enzyme was added, after which 
time a rapid and significant increase in absorbance, concomitant with polymer precipitation 
was observed. Altering a material’s solubility without needing a temperature change is 
potentially attractive for biomedical applications providing, for example, a route towards 
improved, controlled targeting of therapeutic delivery vehicles.65, 66 
 
Figure 8. Isothermal turbidimetry data for Pco5%: Polymer concentration = 5 mg.mL-1; 
Temperature = 34 °C; CIALP added at time indicated by asterisk. Black = control (polymer 
without enzyme); red = polymer with 10 µL CIALP. Inset = representative photo of wells 
before and after experiment. 
 
Finally, the impact of incorporation of the phosphate groups on the cytocompatibility of the 
polymers was evaluated in MCF-7 cells. Cells were incubated with the polymers at 
concentrations ranging from 0.01 to 1 mg.mL-1 for 72 hours and their cell viability 
determined using the MTT (3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide) 
assay. No cytotoxicity was observed for either polymer at the concentrations tested (Figure 
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9). This finding is important as it confirms applicability to biological systems and future 
translational applications. 
 
Figure 9. Cell viability of MCF-7 cells after incubation with polymers for 72 h. pOEGMA300 
(black diamond) and poly(DEGMA-co-Phos-HEMA) 5% (hollow diamonds). Data are 
shown as mean ± standard error of the mean from a minimum of 3 replicates. 
 
The above results demonstrate that by selecting a thermally responsive polymer that is 
‘primed’ to undergo its coil-globule (LCST) transition it is possible to introduce enzyme-
responsivity but only by incorporating a very low loading of the responsive monomers. Such 
an approach is appealing to take advantage of the known advantages and applications of 
thermally responsive polymers (such as selective delivery) but by re-programming them to 
respond to a biological, rather than thermal trigger. We anticipate such materials will find use 
in cellular delivery and imaging. 
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Conclusions 
Here we describe the synthesis of a phosphorylated methacrylate (Phos-HEMA) which is 
well tolerated by the RAFT methodology to produce phosphate-functional polymers. The 
susceptibility of these polymers to the action of the enzyme calf intestinal alkaline 
phosphatase was also demonstrated with no obvious effect of polymer molecular weight on 
the phosphate release profiles, in all cases a maximum of ~ 60 % of phosphate release was 
observed. Guided by this, PhosHEMA was co-polymerised with diethylene glycol methyl 
ether methacrylate (DEGMA) to produce thermally-responsive materials. The cloud point of 
these polymers was tuneable by changing the percentage of Phos-HEMA; the inclusion of 
between 1 and 10 % resulting in a cloud point increase from 35 °C to 45 °C.  An isothermal 
response was shown, as the cloud point of these polymers was observed to decrease in the 
presence of calf intestinal alkaline phosphatase due to enzyme-mediated dephosphorylation to 
the more hydrophobic hydroxyl functional group. This switch was used to modulate the 
polymer solubility isothermally, enabling cloud point activation by the enzyme, without a 
temperature change. Preliminary cytotoxicological evaluation showed no toxicity, confirming 
the polymers potential for biomedical applications. This work demonstrates a practical 
method to introduce enzymatic response into synthetic polymers with the aim of enabling 
them to respond to extra-cellular cues, rather an externally applied stimuli, and may find 
application in drug delivery and biomedicine.  
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